$JXR (01951.HK)$ During the trading session, it rose over 11%, and as of the time of writing, it is reported at 3.1 Hong Kong dollars, with a trading volume of 0.344 billion Hong Kong dollars.

Bank of America Securities released a Research Report stating that with the completion of the new hospital building in Shenzhen, the bank has lowered its capital expenditure forecast starting in 2025. The bank believes that JXR will benefit from recent stimulus policies, such as including in vitro fertilization (IVF) in Medical Insurance and subsidies for newborns in China. The signing of 17 new doctors in the USA provides significant visibility for overseas Business growth.

BOCOM INTL pointed out that the policy dividends are gradually taking effect: Hohhot recently released implementation details for child-rearing subsidies, and the bank expects more regions to follow suit and launch additional fertility support measures. The USA's fertility benefit policies are also in an expansion phase, with 21 states having signed a mandatory Medical Insurance plan for IVF, thus expanding corporate coverage. The bank has a more optimistic outlook for 2026 and long-term performance, with subsequent catalysts mainly deriving from: the cyclical growth dividend brought about by pro-natal policies; capacity expansion following the completion of the move to the new building in Shenzhen; the incubation of institutional Business getting on track and likely achieving break-even in the short term; and the overseas aspect, with a steady ramp-up of the USA Business and ongoing expansion in Southeast Asia.

Editor/Rocky